Camurus AB (CAMX) AI Stock Analysis

• Market Cap: kr36.24B
• Dividend Yield: N/A
• Average Volume (3M): 126.83K
• Price to Earnings (P/E): 45.8
• Beta (1Y): 0.72
• Revenue Growth: 39.37%
• EPS Growth: 189.04%
• Country: SE
• Employees: 238
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 3.27
• Shares Outstanding: 59,848,633
• 10 Day Avg. Volume: 148,560
• 30 Day Avg. Volume: 126,834
• PEG Ratio: -15.28
• Price to Book (P/B): 9.97
• Price to Sales (P/S): 17.56
• P/FCF Ratio: 91.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: kr691.00 ▲(14.12% Upside)

Camurus AB's strong financial performance and robust earnings call results are offset by mixed technical indicators and high valuation concerns. The company's strategic R&D advancements and solid cash position support its growth potential, but challenges in revenue guidance and market conditions warrant caution.

Positive Factors

Strong Financial Health

A low debt-to-equity ratio reflects financial stability, allowing Camurus to invest in growth opportunities without significant financial risk.

R&D Advancements

The advancement in R&D and new drug designations enhance Camurus's competitive edge and potential for future revenue streams.

Cash Position Improvement

A strong cash position provides financial flexibility to support strategic initiatives and buffer against market uncertainties.

Negative Factors

Lowered Revenue Guidance

Lowered revenue guidance indicates potential challenges in meeting growth expectations, which could impact investor confidence and future planning.

Buvidal Sales Slowdown

Slowed sales of Buvidal, a key product, could affect revenue stability and market share in the European market if issues persist.

Challenges in U.K. Market

Funding delays in the U.K. market could hinder sales growth and market penetration, impacting overall performance in a key region.

Camurus AB Business Overview & Revenue Model

Company Description

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

How the Company Makes Money

Camurus generates revenue primarily through the sale of its proprietary pharmaceutical products, including those developed using its FluidCrystal® technology. The company earns money through direct sales of its products, licensing agreements, and collaborations with other pharmaceutical companies. Key revenue streams include royalties from licensed products, milestone payments from partners as they achieve specific development or sales targets, and sales of its marketed products in various global markets. Additionally, Camurus has established strategic partnerships with larger pharmaceutical firms, which enhance its research capacity and market reach, further contributing to its overall earnings.

Camurus AB Financial Statement Overview

Summary

Camurus AB demonstrates strong financial health with high profitability and a solid balance sheet. The company maintains a low debt-to-equity ratio and strong cash flow generation, although recent declines in free cash flow growth warrant monitoring.

Income Statement

Camurus AB has demonstrated strong revenue growth and profitability. The TTM data shows a gross profit margin of 93.5% and a net profit margin of 31.7%, indicating efficient cost management and strong profitability. Revenue growth rate has been positive, although it has slowed compared to previous years. The EBIT and EBITDA margins are robust, reflecting operational efficiency.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.027, indicating low leverage and financial stability. The return on equity is healthy at 20.9%, showcasing effective use of equity to generate profits. The equity ratio is strong, suggesting a well-capitalized structure.

Cash Flow

Camurus AB's cash flow position is stable, with a high operating cash flow to net income ratio of 1.53, indicating strong cash generation relative to net income. However, free cash flow growth has been negative recently, which could be a concern if it persists. The free cash flow to net income ratio remains strong at 0.88.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.35B	1.87B	1.72B	956.34M	600.57M	336.00M
Gross Profit	2.19B	1.74B	1.59B	853.08M	515.22M	300.71M
EBITDA	1.02B	568.24M	562.54M	87.59M	-97.72M	-196.58M
Net Income	781.67M	428.39M	431.44M	55.55M	-90.45M	-167.26M
Balance Sheet
Total Assets	4.63B	3.76B	1.91B	1.31B	1.08B	1.04B
Cash, Cash Equivalents and Short-Term Investments	3.51B	2.85B	1.19B	565.54M	411.57M	461.79M
Total Debt	106.31M	17.04M	24.51M	26.22M	25.66M	25.48M
Total Liabilities	510.02M	467.33M	414.82M	310.82M	232.99M	196.66M
Stockholders Equity	4.12B	3.29B	1.49B	994.67M	848.91M	847.44M
Cash Flow
Free Cash Flow	605.14M	358.62M	596.75M	99.29M	-148.37M	-242.16M
Operating Cash Flow	717.12M	387.99M	606.88M	101.20M	-143.43M	-238.83M
Investing Cash Flow	-112.62M	-29.37M	-10.13M	5.38M	-4.94M	-3.33M
Financing Cash Flow	170.64M	1.30B	28.76M	43.70M	98.90M	347.85M

Camurus AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 605.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Positive. The current price of 605.5 is above the 20-day moving average (MA) of 603.67, below the 50-day MA of 618.11, and below the 200-day MA of 631.04, indicating a neutral trend. The MACD of -5.98 indicates Negative momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CAMX.

Camurus AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOA.B	76 Outperform	kr28.15B	28.10	68.77%	―	1046.53%	―
CAMX	73 Outperform	kr36.24B	45.78	20.86%	―	39.37%	189.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BINV	47 Neutral	kr1.91B	-5.88	-36.52%	―	533.73%	20.92%
XSPRAY	47 Neutral	kr1.25B	-5.10	-35.03%	―	―	25.14%
VICO	45 Neutral	kr2.76B	-5.34	-71.87%	―	-91.85%	-6.65%
HNSA	41 Neutral	kr2.99B	-3.30	―	―	-5.69%	21.58%

Camurus AB Corporate Events

Camurus Increases Shares and Votes Following Employee Stock Option Exercise

Camurus has announced an increase in its number of shares and votes following the exercise of 24,200 employee stock options from its ESOP 2022/2026 program. This increase reflects the company’s ongoing commitment to employee participation and could potentially enhance its market positioning by aligning employee interests with corporate growth.

Camurus Announces Nomination Committee for AGM 2026

Camurus has announced the appointment of its Nomination Committee for the Annual General Meeting (AGM) 2026, consisting of representatives from major shareholders holding about 40% of the company’s shares and votes. This committee will present its proposals in the Notice to the AGM 2026, and shareholders are invited to submit their proposals by specified deadlines. The AGM is scheduled for 28 May 2026 in Lund, Sweden.

Camurus Reports Positive Phase 1b Results for Monthly Semaglutide Depot

Camurus announced promising results from a Phase 1b study of CAM2056, a monthly semaglutide formulation, showing significant weight and A1c reductions compared to weekly semaglutide. The study indicates CAM2056’s potential for convenient monthly dosing with rapid initiation, positioning Camurus as a competitive player in the obesity and type 2 diabetes treatment market.

Camurus AB Reports Strong Q3 2025 Financial Performance and Strategic Milestones

Camurus AB reported significant financial growth in the third quarter of 2025, with total revenues increasing by 18% to SEK 567 million and profit before tax rising by 48% to SEK 245 million. The company achieved notable milestones, including the UK approval of Oczyesa® for acromegaly treatment and orphan drug designations for CAM2029 in the US and Europe. Despite lowering its revenue guidance for 2025, Camurus maintained its profit forecast, reflecting strong operational performance and strategic positioning in the biopharmaceutical industry.

Camurus Increases Shares and Votes Following Employee Stock Option Exercise

Camurus has announced an increase in its number of shares and votes following the exercise of 188,050 employee stock options from its ESOP 2022/2026 program. This change reflects the company’s ongoing commitment to employee participation and could impact its market positioning by potentially enhancing shareholder value.